Fig. 3: Distinct DepOR among EML4-ALK models and adaptive immunity requirement for maximal DepOR.
From: Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
a The tumor volumes (fold change from initial) after 2 weeks of alectinib treatment in the EA models (see Fig. 2a) were analyzed by one-way ANOVA (Kruskal–Wallis test). b Tumor-bearing mice treated for 3 weeks with alectinib (Residual, from Fig. 2) were followed by μCT for another 2 weeks after termination of daily TKI treatment. The tumor volumes relative to initial pre-treatment volumes are presented and the data were analyzed by one-way ANOVA. c The residual disease volumes measured after 2 weeks of alectinib treatment in C57BL/6 were compared to Nu/Nu hosts by two-tail t tests. In the graphs, the error bars are the standard error of the mean and dots represent individual tumors. *, **, ***, and **** indicate p values <0.05, <0.01, <0.001 and <0.0001 respectively.
